Trials
2 active
2 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Conventional Chondrosarcoma, Ewing Sarcoma, Colorectal Adenocarcinoma
- Main trialPhase 2
- “Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.”In the company’s words, NCT04950075 on ClinicalTrials.gov
Other drugs for Ewing Sarcoma
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2
- EntrectinibRoche · Phase 1/2
- LurbinectedinJazz Pharmaceuticals · Phase 1/2
- Zilovertamab vedotinMerck & Co. · Phase 1/2
- AbemaciclibEli Lilly · Phase 2
- VAL-413Valent Technologies, LLC · Phase 1
Coming up1
- Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 30 Sep 2025 | Study of INBRX-109 in Conventional Chondrosarcoma | |
| Phase 1Recruiting | Dec 2028 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026